Telix Pharmaceuticals recently hosted an educational webinar titled 'Neuro-Oncology Portfolio Update and Physician Perspectives on Future Therapeutic Directions.' The event focused on the company's latest developments in neuro-oncology, including targeted radiopharmaceuticals for brain cancers.
During the webinar, physicians discussed emerging therapeutic approaches, such as peptide receptor radionuclide therapy (PRRT) and antibody-drug conjugates, for treating glioblastoma and other central nervous system tumors. Telix highlighted its pipeline candidates, including TLX101 (a 131I-IPA agent) for glioblastoma, which is in clinical development.
The webinar also covered challenges in drug delivery across the blood-brain barrier and the potential of theranostics—combining diagnostic imaging with targeted therapy—to improve patient outcomes. No specific new data or trial results were disclosed during the session.
